potassium-magnesium-aspartate and Cholestasis

To observe the efficacy and safety of ademetionine in the treatment of viral hepatitis with intrahepatic biliary stasis.. In this series, 110 patients with viral hepatitis associated intrahepatic biliary stasis were randomly divided into Groups A and B. Patients in Group A received ademetionine for four weeks. Patients in Group B received potassium magnesium aspartate for four weeks.. In Group A, at the end of treatment, the effective rate for skin pruritus in patients with cholestatic hepatitis was 86.67% (13/15), and the effective rate for skin pruritus and anorexia were 88.24% (15/17) and 82.35% (14/17), respectively in patients with chronic hepatitis combining intrahepatic cholestasis, which were significantly higher than that in Group B (P<0.05). STB, SCB, TBA, ALT and AST were lower in Group A than Group B (P<0.05). The decrease of ALP and the increase of albumin after treatment were more significant in Group A than in Group B (P<0.05).. Ademetionine has better efficacy than potassium magnesium aspartate in the treatment of patients with cholestatic viral hepatitis.

Topics: Adolescent; Adult; Aged; Cholestasis; Female; Hepatitis, Viral, Human; Humans; Male; Middle Aged; Potassium Magnesium Aspartate; S-Adenosylmethionine